Pittsburgh, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that Stephen Sands has joined the Company’s Board of Directors. Mr. Sands, the Vice Chairman of Investment Banking and Chairman of the Global Healthcare Group at Lazard, has built a 25-year career providing strategic and financial advice to senior executives and boards of directors at leading healthcare and life sciences companies globally.
“Stephen is a highly accomplished professional whose extensive experience both advising and building biotechnology companies will provide an extraordinary and critical perspective to Cognition as we advance our pipeline of neurology candidates, beginning with CT1812, through their critical development programs.” said Kenneth I. Moch, President and Chief Executive Officer of Cognition Therapeutics.
Robert Gailus, Chairman of Cognition, added “Stephen’s perspective and counsel, and his extensive knowledge of the financial landscape will be invaluable as we build and position Cognition to address the unmet need for treating Alzheimer's disease.”
Prior to joining Lazard, a financial advisory and asset management firm, Mr. Sands was a partner in the healthcare practice of McKinsey & Company. During his career, he has co-founded two life sciences companies: Enzytech (acquired by Alkermes) and Opta Food Ingredients (acquired by Stake Technology). Mr. Sands has also served as director on the boards of several life sciences companies, including National Imaging Associates, Inc. (acquired by Magellan Health Services), and Isogen LLC (acquired by Monsanto).
Mr. Sands is a member of the Rockefeller University Counsel, the Washington University (St. Louis) School of Engineering & Applied Science National Counsel, the National Campaign Committee and the New York Regional Cabinet; a trustee and co-chair of the nominating and governance committee of the New York Hall of Science; and a member of the Columbia University Science Advisory Committee. He earned a Bachelor of Arts in biology from Oberlin College, a Bachelor of Science and Master of Science in chemical engineering from Washington University in St. Louis, and a Master of Business Administration with a concentration in finance from New York University.
“Joining Cognition’s Board affords me a unique opportunity to support the development of CT1812, an innovative and differentiated approach to the treatment of Alzheimer's disease, one of the most complex and devastating diseases of our time and a disease for which there is an urgent need for new treatments which have the potential to be disease modifying,” said Mr. Sands.
About Cognition Therapeutics, Inc.
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class, orally available small molecule. This highly brain penetrant compound targets the sigma-2/PGRMC1 receptor complex, displacing toxic beta amyloid oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. In Cognition’s ongoing completed Study COG0102, patients with mild-to-moderate Alzheimer’s disease are being randomized to one of three doses of CT1812 or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Additional information about Cognition may be found online at http://www.cogrx.com.
Source:Cognition Therapeutics, Inc.